Lannett Company, Inc. (NYSE:LCI) saw a large decrease in short interest in August. As of August 15th, there was short interest totalling 16,909,700 shares, a decrease of 17.8% from the July 15th total of 20,576,700 shares. Based on an average daily volume of 1,210,000 shares, the short-interest ratio is currently 14.0 days. Approximately 60.8% of the company’s stock are short sold.
A number of equities analysts have issued reports on the company. ValuEngine raised Lannett from a “sell” rating to a “hold” rating in a research report on Tuesday, July 2nd. Zacks Investment Research lowered Lannett from a “buy” rating to a “hold” rating in a research report on Wednesday, July 17th. Four investment analysts have rated the stock with a hold rating, Lannett presently has an average rating of “Hold” and a consensus price target of $9.38.
Shares of NYSE LCI traded down $0.20 during trading on Tuesday, reaching $6.03. The stock had a trading volume of 2,155,299 shares, compared to its average volume of 1,320,490. Lannett has a one year low of $3.33 and a one year high of $10.45. The company has a debt-to-equity ratio of 2.10, a quick ratio of 2.12 and a current ratio of 2.88. The stock has a market cap of $243.39 million, a PE ratio of 1.95 and a beta of 2.41. The firm’s 50 day moving average price is $6.45 and its two-hundred day moving average price is $7.02.
Lannett Company, Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages.
Featured Story: What does a dividend yield signify to investors?
Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.